[{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xalud Therapeutics Appoints Diem Nguyen, Ph.D., as Chief Executive Officer","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xalud Therapeutics\u2019 XT-150, Achieves Multiple Clinical Milestones in Pathologic Inflammation and Neuroimmunology Therapeutic Areas","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"PBM Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xalud Therapeutics Completes Oversubscribed $30 Million Series C Financing","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xalud Therapeutics Receives FDA Fast Track Designation for XT-150 for the Treatment of Pain Associated with Osteoarthritis of the Knee","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xalud Therapeutics Doses First Patient in Phase 2a Trial of XT-150 for the Treatment of Facet Joint Osteoarthritis Pain","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Xalud Therapeutics
The trial will enroll up to 60 participants in one of two XT-150, a locally-injectable plasmid DNA gene therapy expressing IL-10v, dose groups or placebo for the treatment of facet joint osteoarthritis pain.
Fast Track designation is supportive of the clinical significance of our lead candidate, XT-150 that leverages plasmid DNA encoding the anti-inflammatory cytokine IL-10v for the treatment of pain associated with osteoarthritis of the knee.
The financing positioned Xalud’s to continue advancing lead therapeutic candidate, XT-150, a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, through clinical development and further expand our platform
The primary efficacy evaluation of two potential therapeutic doses of XT-150 (150 and 450 μg) will be assessed at six months, followed by an additional six-month safety follow-up with the opportunity for a second injection. Topline results are expected in 4th quarter of 2021.
XT-150 is currently in a Phase II/III trial for osteoarthritis, and Nguyen expects to read out topline Phase IIb data in Q4. XT-150, is a locally injectable plasmid DNA gene therapy expressing Interleukin 10 (IL-10).